Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Our findings suggest that combinatorial inhibition of CK2 and KIT warrants evaluation as a novel therapeutic strategy in GIST, especially in imatinib-resistant GIST.
|
31776458 |
2020 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
This case illustrates that knowing the specific type of KIT mutations may uncover resistance of certain GIST's to TKIs, necessitating more targeted and alternative therapy.
|
31702819 |
2020 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Additional genetic events including RB1, SMARCB1, and MAX except secondary KIT/PDGFRA mutations are the most common for GISTs to evolve into resistant disease.
|
31758409 |
2020 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Gastrointestinal stromal tumors (GISTs) are one of the most common mesenchymal tumor types and usually contain KIT or PDGFRA mutations.
|
31570771 |
2020 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
WEE1 inhibition could promote KIT autophagic degradation and, therefore, targeting WEE1 might represent a novel strategy for GIST therapies.
|
31197522 |
2020 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different <i>KIT</i> mutations, with differential sensitivity to standard TKI.<b>Experimental Design:</b> NMRI <i>nu/nu</i> mice (<i>n</i> = 93) were transplanted with human GIST xenografts with <i>KIT</i> exon 11+17 (UZLX-GIST9 <i>
|
30274985 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) constitute a small KIT/PDGFRA-WT GIST subgroup featuring DNA methylation which, although pervasive, appears nevertheless not randomly distributed.
|
30616628 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.
|
31085175 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Around 90% of GISTs contain mutations in KIT or PDGFRA and the remaining 10% of GISTs are wild-type.
|
30003531 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
AlteredExpression
|
group |
BEFREE |
CeRNA Expression Profiling Identifies KIT-Related circRNA-miRNA-mRNA Networks in Gastrointestinal Stromal Tumour.
|
31552107 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Patients with KIT exon 11 mutations had better PFS compared to those with KIT exon 9 mutations or wild-type GISTs (p = .017, p = .040, respectively).
|
30346846 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors.
|
31076599 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Furthermore, DEPDC5 modulates the sensitivity of GIST to KIT inhibitors, and the combination therapy with mTOR inhibitor and KIT inhibitor may work better in GIST patients with DEPDC5 inactivation.
|
31636198 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Approximately 15% of adult patients with GISTs are negative for mutations in KIT or PDGFRA genes.
|
31708372 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The IHC characteristic of GIST in descending order showed positivity for vimentin (88.9%), CD117 (83.3%), CD34 (77.8%), Ki67 (63.9%), SMA (38.9%), desmin (27.8%), and S100 (19.4%).
|
30723856 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Succinate dehydrogenase (SDH)-deficient GISTs are wild type and lack KIT proto-oncogene receptor tyrosine kinase and platelet-derived growth factor receptor A ( KIT or PDGFRA) mutations.
|
30301441 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
We performed RNA sequencing of 75 human GIST tumors from 75 patients, comprising the largest cohort of GISTs sequenced to date, in order to discover differences in the immune infiltrates of KIT and PDGFRA-mutant GIST.
|
30762585 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Combinations with KIT or MEK inhibitors completely abrogated GIST-survival signaling and displayed synergistic effects.
|
31308077 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Dual inhibition of KIT and MAPK pathways has synergistic antitumor activity in preclinical GIST models.
|
31213500 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Dedifferentiation in GIST is a rare histologic change which may occur de novo or secondary to imatinib therapy and is characterized by abrupt transition of well-differentiated (WD) GIST to a subclonal anaplastic process that shows loss of immunohistochemical marks (CD117, DOG1).
|
31072206 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The prognosis and the clinical course of these tumors is different from that of KIT- or PDGFR-α-mutated GISTs.
|
31169996 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
The pathological findings were compatible with GIST and the tumor consisted of spindle cells with positive staining for KIT, CD34, and DOG1 and negative or weak staining for desmin and S-100 protein.
|
30943904 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.
|
31250638 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
Biomarker
|
group |
BEFREE |
Taken together, these results demonstrate the existence of a nuclear KIT-driven NFKBIB-RELA-KIT autoregulatory loop in GIST tumorigenesis, which are potential targets for developing combination therapy to overcome imatinib-resistant of KIT-expressing GISTs.
|
31363162 |
2019 |
Gastrointestinal Stromal Tumors
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In particular, a discovery cohort (34 GIST with a KIT exon 11 primary mutation, and no toxicity) was analyzed through DMET array that interrogates 1936 variants in 231 genes of the ADME process.
|
30237583 |
2019 |